JP2010505386A5 - - Google Patents

Download PDF

Info

Publication number
JP2010505386A5
JP2010505386A5 JP2009511025A JP2009511025A JP2010505386A5 JP 2010505386 A5 JP2010505386 A5 JP 2010505386A5 JP 2009511025 A JP2009511025 A JP 2009511025A JP 2009511025 A JP2009511025 A JP 2009511025A JP 2010505386 A5 JP2010505386 A5 JP 2010505386A5
Authority
JP
Japan
Prior art keywords
cycle arrest
cell cycle
induction
cell
cdki protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009511025A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505386A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/011623 external-priority patent/WO2007133773A2/en
Publication of JP2010505386A publication Critical patent/JP2010505386A/ja
Publication of JP2010505386A5 publication Critical patent/JP2010505386A5/ja
Pending legal-status Critical Current

Links

JP2009511025A 2006-05-15 2007-05-15 Cdki経路阻害剤の同定 Pending JP2010505386A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74721306P 2006-05-15 2006-05-15
PCT/US2007/011623 WO2007133773A2 (en) 2006-05-15 2007-05-15 Identification of cdki pathway inhibitors

Publications (2)

Publication Number Publication Date
JP2010505386A JP2010505386A (ja) 2010-02-25
JP2010505386A5 true JP2010505386A5 (https=) 2010-07-08

Family

ID=38694544

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009511025A Pending JP2010505386A (ja) 2006-05-15 2007-05-15 Cdki経路阻害剤の同定

Country Status (6)

Country Link
US (1) US20080033000A1 (https=)
EP (1) EP2021019A4 (https=)
JP (1) JP2010505386A (https=)
AU (1) AU2007249762A1 (https=)
CA (1) CA2652341A1 (https=)
WO (1) WO2007133773A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1684762A4 (en) 2003-11-13 2009-06-17 Ambit Biosciences Corp UREA DERIVATIVES AS MODULATORS OF KINASE
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
US8466290B2 (en) * 2008-07-10 2013-06-18 Pharma Ip General Incorporated Association STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient
US20100190807A1 (en) * 2008-08-26 2010-07-29 Senex Biotechnology, Inc. CDKI Pathway inhibitors and uses thereof to regulate expression to TAU protein
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
CA2840627A1 (en) 2011-06-29 2013-01-03 Otsuka Pharmaceutical Co., Ltd. Quinazolines as therapeutic compounds and related methods of use
KR20150023223A (ko) * 2012-02-02 2015-03-05 세넥스 바이오테크놀러지 인코포레이티드 Cdk8/cdk19 선택성 억제제 및 암에 대한 항-전이 및 화학예방 방법에서 이들의 용도
NZ732511A (en) * 2014-12-15 2018-11-30 Univ Michigan Regents Small molecule inhibitors of egfr and pi3k
PL3484474T3 (pl) 2016-07-13 2024-08-26 The Children's Medical Center Corporation Związki fenotiazyny do leczenia zaburzeń rybosomalnych i rybosomopatii
CA2994329A1 (en) * 2017-06-08 2018-12-08 The Children's Medical Center Corporation Compounds and methods for treatment of diamond blackfan anemia
RU2763347C2 (ru) * 2018-03-01 2021-12-28 Закрытое Акционерное Общество "Биокад" Новые ингибиторы cdk8/19
US20220388962A1 (en) * 2019-08-22 2022-12-08 Biohaven Therapeutics Ltd. Molecules that bind to tdp-43 for the treatment of amyotrophic lateral sclerosis and related disorders
WO2025024311A2 (en) * 2023-07-21 2025-01-30 Icahn School Of Medicine At Mount Sinai G9a/glp inhibitors and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9922173D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
EP1578722A4 (en) * 2001-10-12 2006-09-06 Irm Llc KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
EP2650286A1 (en) * 2004-02-19 2013-10-16 Rexahn Pharmaceuticals, Inc. Quinazoline derivatives and therapeutic use thereof
JP2007534735A (ja) * 2004-04-28 2007-11-29 アロウ セラピューティクス リミテッド 抗ウイルス剤として使用するためのモルホリニルアニリノキナゾリン誘導体
US8592147B2 (en) * 2005-01-13 2013-11-26 Senex Biotechnology High-content screening for drugs against cancer and age-related diseases

Similar Documents

Publication Publication Date Title
JP2010505386A5 (https=)
JP2011508438A5 (https=)
JP2012507448A5 (https=)
JP2011528458A5 (https=)
JP2010518805A5 (https=)
JP2008501714A5 (https=)
JP2010538767A5 (https=)
JP2010219032A5 (https=)
DK2035398T3 (da) Immobiliseret 1,2-benzisothioazolin-3-on
EP2023715A4 (en) Indoleamine-2,3-dioxygenase 2
ATE512132T1 (de) Hydrochloridsalz von 5-ä3-(3- hydroxyphenoxy)azetidin-1-ylü-5-methyl-2,2- diphenylhexanamid
DE602006018127D1 (de) Acetylenderivate
JP2012043586A5 (https=)
JP2011246422A5 (https=)
DE602006012689D1 (de) Überprüfungsverfahren
JP2008517002A5 (https=)
DE602006001668D1 (de) Fehlerüberprüfungsverfahren
JP2006522596A5 (https=)
DE502006002221D1 (de) Piezoaktor mit innenliegender kontaktierung
NL1030303A1 (nl) Tweewieler.
JP2011249271A5 (https=)
DE602006004709D1 (de) Beschichtungsverfahren
JP2008545704A5 (https=)
DE602006003519D1 (de) Aufzeichnungsverfahren
CN301013200S (zh) 衣物净化机